{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:53:50Z","timestamp":1781704430503,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Metab Health Dis"],"DOI":"10.1038\/s44324-026-00115-3","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:17:12Z","timestamp":1781695032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD59 drives diet-induced obesity and glucose intolerance, insulin resistance, and metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1038","volume":"4","author":[{"given":"Marian","family":"Zeibak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netanel","family":"Karbian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Riahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saja","family":"Baraghithy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Labiba","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Tabib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifat","family":"Abromovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Agranovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Benyamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Dor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Mevorach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"115_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cellimm.2017.03.001","volume":"315","author":"A Asghar","year":"2017","unstructured":"Asghar, A. & Sheikh, N. Role of immune cells in obesity induced low grade inflammation and insulin resistance. Cell. Immunol. 315, 18\u201326 (2017).","journal-title":"Cell. Immunol."},{"key":"115_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1146\/annurev-physiol-021909-135846","volume":"72","author":"JM Olefsky","year":"2010","unstructured":"Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219\u2013246 (2010).","journal-title":"Annu. Rev. Physiol."},{"key":"115_CR3","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","volume":"383","author":"SE Kahn","year":"2014","unstructured":"Kahn, S. E., Cooper, M. E. & Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 383, 1068\u20131083 (2014).","journal-title":"Lancet."},{"key":"115_CR4","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.5888\/pcd14.160287","volume":"14","author":"JX Moore","year":"2017","unstructured":"Moore, J. X., Chaudhary, N. & Akinyemiju, T. Metabolic syndrome prevalence by race\/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev. Chronic Dis. 14, E24 (2017).","journal-title":"Prev. Chronic Dis."},{"key":"115_CR5","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.2337\/dci23-0035","volume":"46","author":"K Khunti","year":"2023","unstructured":"Khunti, K. et al. Diabetes and multiple long-term conditions: a review of our current global health challenge. Diabetes Care 46, 2092\u20132101 (2023).","journal-title":"Diabetes Care"},{"key":"115_CR6","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport, M. J. Complement. First of two parts. N. Engl. J. Med. 344, 1058\u20131066 (2001).","journal-title":"N. Engl. J. Med."},{"key":"115_CR7","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport, M. J. Complement. Second of two parts. N. Engl. J. Med. 344, 1140\u20131144 (2001).","journal-title":"N. Engl. J. Med."},{"key":"115_CR8","doi-asserted-by":"crossref","unstructured":"K\u00f6hl, J. Self, non-self, and danger: a complementary view. Adv. Exp. Med. Biol. 586, 71\u201394 (2006).","DOI":"10.1007\/0-387-34134-X_6"},{"key":"115_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/0167-5699(91)90005-E","volume":"12","author":"PJ Lachmann","year":"1991","unstructured":"Lachmann, P. J. The control of homologous lysis. Immunol. Today 12, 312\u2013315 (1991).","journal-title":"Immunol. Today"},{"key":"115_CR10","first-page":"1","volume":"71","author":"S Meri","year":"1990","unstructured":"Meri, S. et al. Human protectin (CD59), an 18,000-20,000\u2009MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71, 1\u20139 (1990).","journal-title":"Immunology"},{"key":"115_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1172\/JCI114172","volume":"84","author":"MH Holguin","year":"1989","unstructured":"Holguin, M. H., Fredrick, L. R., Bernshaw, N. J., Wilcox, L. A. & Parker, C. J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 84, 7\u201317 (1989).","journal-title":"J. Clin. Invest."},{"key":"115_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2012-07-441857","volume":"121","author":"Y Nevo","year":"2013","unstructured":"Nevo, Y. et al. CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy. Blood 121, 129\u2013135 (2013).","journal-title":"Blood"},{"key":"115_CR13","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ejpn.2015.07.001","volume":"19","author":"B Ben-Zeev","year":"2015","unstructured":"Ben-Zeev, B. et al. Devastating recurrent brain ischemic infarctions and retinal disease in pediatric patients with CD59 deficiency. Eur. J. Paediatr. Neurol. 19, 688\u2013693 (2015).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"115_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.molimm.2015.03.005","volume":"67","author":"D Mevorach","year":"2015","unstructured":"Mevorach, D. Paroxysmal nocturnal hemoglobinuria (PNH) and primary p.Cys89Tyr mutation in CD59: differences and similarities. Mol. Immunol. 67, 51\u201355 (2015).","journal-title":"Mol. Immunol."},{"key":"115_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/ana.24770","volume":"80","author":"D Mevorach","year":"2016","unstructured":"Mevorach, D. et al. Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation. Ann. Neurol. 80, 708\u2013717 (2016).","journal-title":"Ann. Neurol."},{"key":"115_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.thromres.2018.06.006","volume":"168","author":"A Tabib","year":"2018","unstructured":"Tabib, A. et al. Prothrombotic mechanisms in patients with congenital p.Cys89Tyr mutation in CD59. Thromb. Res. 168, 67\u201377 (2018).","journal-title":"Thromb. Res."},{"key":"115_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.molimm.2017.05.024","volume":"89","author":"A Tabib","year":"2017","unstructured":"Tabib, A., Karbian, N. & Mevorach, D. Demyelination, strokes, and eculizumab: lessons from the congenital CD59 gene mutations. Mol. Immunol. 89, 69\u201372 (2017).","journal-title":"Mol. Immunol."},{"key":"115_CR18","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cmet.2014.03.001","volume":"19","author":"U Krus","year":"2014","unstructured":"Krus, U. et al. The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events. Cell Metab. 19, 883\u2013890 (2014).","journal-title":"Cell Metab."},{"key":"115_CR19","doi-asserted-by":"publisher","first-page":"12425","DOI":"10.1096\/fj.201901007R","volume":"33","author":"E Golec","year":"2019","unstructured":"Golec, E. et al. A cryptic non-GPI-anchored cytosolic isoform of CD59 controls insulin exocytosis in pancreatic beta-cells by interaction with SNARE proteins. FASEB J. 33, 12425\u201312434 (2019).","journal-title":"FASEB J."},{"key":"115_CR20","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1212\/NXG.0000000000000280","volume":"4","author":"N Karbian","year":"2018","unstructured":"Karbian, N. et al. Molecular pathogenesis of human CD59 deficiency. Neurol. Genet. 4, e280 (2018).","journal-title":"Neurol. Genet."},{"key":"115_CR21","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.4049\/jimmunol.165.5.2528","volume":"165","author":"YM Qian","year":"2000","unstructured":"Qian, Y. M. et al. Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59. J. Immunol. 165, 2528\u20132534 (2000).","journal-title":"J. Immunol."},{"key":"115_CR22","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.4049\/jimmunol.158.4.1692","volume":"158","author":"MB Powell","year":"1997","unstructured":"Powell, M. B., Marchbank, K. J., Rushmere, N. K., van den Berg, C. W. & Morgan, B. P. Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J. Immunol. 158, 1692\u20131702 (1997).","journal-title":"J. Immunol."},{"key":"115_CR23","doi-asserted-by":"publisher","first-page":"e2120083119","DOI":"10.1073\/pnas.2120083119","volume":"119","author":"E Golec","year":"2022","unstructured":"Golec, E. et al. Alternative splicing encodes functional intracellular CD59 isoforms that mediate insulin secretion and are down-regulated in diabetic islets. Proc. Natl. Acad. Sci. USA. 119, e2120083119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"115_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/path.4829","volume":"241","author":"JK Lau","year":"2017","unstructured":"Lau, J. K., Zhang, X. & Yu, J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J. Pathol. 241, 36\u201344 (2017).","journal-title":"J. Pathol."},{"key":"115_CR25","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.2337\/db05-1200","volume":"55","author":"MA Abdul-Ghani","year":"2006","unstructured":"Abdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D. & DeFronzo, R. A. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55, 1430\u20131435 (2006).","journal-title":"Diabetes"},{"key":"115_CR26","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","volume":"85","author":"A Katz","year":"2000","unstructured":"Katz, A. et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85, 2402\u20132410 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"115_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1521-690X(03)00042-3","volume":"17","author":"G Pacini","year":"2003","unstructured":"Pacini, G. & Mari, A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best. Pract. Res. Clin. Endocrinol. Metab. 17, 305\u2013322 (2003).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"115_CR28","doi-asserted-by":"publisher","first-page":"e12294","DOI":"10.1016\/j.heliyon.2022.e12294","volume":"8","author":"AN Onyango","year":"2022","unstructured":"Onyango, A. N. Excessive gluconeogenesis causes the hepatic insulin resistance paradox and its sequelae. Heliyon 8, e12294 (2022).","journal-title":"Heliyon"},{"key":"115_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74617-5","volume":"10","author":"H Tsuru","year":"2020","unstructured":"Tsuru, H., Osaka, M., Hiraoka, Y. & Yoshida, M. HFD-induced hepatic lipid accumulation and inflammation are decreased in Factor D deficient mouse. Sci. Rep. 10, 17593 (2020).","journal-title":"Sci. Rep."},{"key":"115_CR30","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.3389\/fimmu.2019.02852","volume":"10","author":"D van der Heide","year":"2019","unstructured":"van der Heide, D., Weiskirchen, R. & Bansal, R. Therapeutic targeting of hepatic macrophages for the treatment of liver diseases. Front. Immunol. 10, 2852 (2019).","journal-title":"Front. Immunol."},{"key":"115_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cmet.2023.12.013","volume":"36","author":"A Ghrayeb","year":"2024","unstructured":"Ghrayeb, A. et al. Serine synthesis via reversed SHMT2 activity drives glycine depletion and acetaminophen hepatotoxicity in MASLD. Cell Metab. 36, 116\u2013129.e117 (2024).","journal-title":"Cell Metab."},{"key":"115_CR32","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.2147\/DMSO.S315488","volume":"14","author":"X Yi","year":"2021","unstructured":"Yi, X. & Cheng, X. Understanding competitive endogenous RNA network mechanism in Type 1 diabetes mellitus using computational and bioinformatics approaches. Diabetes Metab. Syndr. Obes. 14, 3865\u20133945 (2021).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"115_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41586-018-0645-6","volume":"563","author":"E Katsyuba","year":"2018","unstructured":"Katsyuba, E. et al. De novo NAD(+) synthesis enhances mitochondrial function and improves health. Nature 563, 354\u2013359 (2018).","journal-title":"Nature"},{"key":"115_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-020-00311-7","volume":"5","author":"N Xie","year":"2020","unstructured":"Xie, N. et al. NAD(+) metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct. Target Ther. 5, 227 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"115_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37464-z","volume":"9","author":"T Fromme","year":"2019","unstructured":"Fromme, T. et al. Bile acid supplementation decreases body mass gain in C57BL\/6\u2009J but not 129S6\/SvEvTac mice without increasing energy expenditure. Sci. Rep. 9, 131 (2019).","journal-title":"Sci. Rep."},{"key":"115_CR36","doi-asserted-by":"crossref","unstructured":"Virmani, M. A. & Cirulli, M. The role of l-carnitine in mitochondria, prevention of metabolic inflexibility and disease initiation. Int. J. Mol. Sci. 23, 2717 (2022).","DOI":"10.3390\/ijms23052717"},{"key":"115_CR37","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.molmet.2014.06.005","volume":"3","author":"K Singer","year":"2014","unstructured":"Singer, K. et al. Diet-induced obesity promotes myelopoiesis in hematopoietic stem cells. Mol. Metab. 3, 664\u2013675 (2014).","journal-title":"Mol. Metab."},{"key":"115_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cmet.2014.03.029","volume":"19","author":"PR Nagareddy","year":"2014","unstructured":"Nagareddy, P. R. et al. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab. 19, 821\u2013835 (2014).","journal-title":"Cell Metab."},{"key":"115_CR39","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"115_CR40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41574-019-0168-8","volume":"15","author":"FM Gribble","year":"2019","unstructured":"Gribble, F. M. & Reimann, F. Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. Nat. Rev. Endocrinol. 15, 226\u2013237 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"115_CR41","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","volume":"66","author":"DJ Drucker","year":"2023","unstructured":"Drucker, D. J. & Holst, J. J. The expanding incretin universe: from basic biology to clinical translation. Diabetologia 66, 1765\u20131779 (2023).","journal-title":"Diabetologia"},{"key":"115_CR42","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3732\/ajb.1700281","volume":"104","author":"PS Soltis","year":"2017","unstructured":"Soltis, P. S. Digitization of herbaria enables novel research. Am. J. Bot. 104, 1281\u20131284 (2017).","journal-title":"Am. J. Bot."},{"key":"115_CR43","doi-asserted-by":"publisher","first-page":"102192","DOI":"10.1016\/j.molmet.2025.102192","volume":"98","author":"M Ahmad","year":"2025","unstructured":"Ahmad, M. et al. Metabolic consequences of altered kidney glucose reabsorption under normoglycemic conditions. Mol. Metab. 98, 102192 (2025).","journal-title":"Mol. Metab."},{"key":"115_CR44","doi-asserted-by":"crossref","unstructured":"Kogot-Levin, A. et al. Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition. JCI Insight 8, 64296 (2023).","DOI":"10.1172\/jci.insight.164296"},{"key":"115_CR45","unstructured":"MMPC. Hepatic Gluconeogenesis (US National Institutes of Health (NIH), 2013)."},{"key":"115_CR46","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"115_CR47","doi-asserted-by":"publisher","unstructured":"Ghrayeb, A. et al. Fatty liver-mediated glycine restriction impairs glutathione synthesis and causes hypersensitization to acetaminophen. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.01.16.524043 (2023).","DOI":"10.1101\/2023.01.16.524043"}],"container-title":["npj Metabolic Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00115-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00115-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00115-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:02:52Z","timestamp":1781701372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00115-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["115"],"URL":"https:\/\/doi.org\/10.1038\/s44324-026-00115-3","relation":{},"ISSN":["2948-2828"],"issn-type":[{"value":"2948-2828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"19 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dror Mevorach is the founder and shareholder of Enlivex Therapeutics (NASDAQ) that has no relation to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}